168 related articles for article (PubMed ID: 23635842)
41. Effects of suspending ACE inhibitors and ARBs in advanced chronic kidney disease.
Díaz-Domínguez ME; Fernández-Lucas M; Gomis-Couto A; Ruiz-Roso G; Teruel JL; Quereda C
Nefrologia; 2012 May; 32(3):400-1. PubMed ID: 22592428
[No Abstract] [Full Text] [Related]
42. Non-angiotensin effects of angiotensin-converting enzyme inhibitors.
Sunman W; Sever PS
Clin Sci (Lond); 1993 Dec; 85(6):661-70. PubMed ID: 8287657
[No Abstract] [Full Text] [Related]
43. Effect of single or dual blockade of renin-angiotensin system in acute myocardial infarction patients according to renal function.
Jeong HC; Jeong JM; Jeong MH; Ahn Y; Chae SC; Hur SH; Hong TJ; Kim YJ; Seong IW; Chae JK; Rhew JY; Chae IH; Cho MC; Bae JH; Rha SW; Kim CJ; Choi D; Jang YS; Yoon J; Chung WS; Cho JG; Seung KB; Park SJ;
Int J Cardiol; 2012 Jun; 157(3):408-11. PubMed ID: 22513185
[No Abstract] [Full Text] [Related]
44. Angiotensin-converting enzyme inhibitors and angioedema: estimating the risk.
Weber MA; Messerli FH
Hypertension; 2008 Jun; 51(6):1465-7. PubMed ID: 18413486
[No Abstract] [Full Text] [Related]
45. Comparative effectiveness of angiotensin receptor blockers vs. angiotensin-converting enzyme inhibitors on cardiovascular outcomes in patients initiating peritoneal dialysis.
Shen JI; Saxena AB; Montez-Rath ME; Leng L; Chang TI; Winkelmayer WC
J Nephrol; 2017 Apr; 30(2):281-288. PubMed ID: 27485007
[TBL] [Abstract][Full Text] [Related]
46. Preadmission use of renin-angiotensin blockers and rupture of abdominal aortic aneurysm: a nationwide, population-based study.
Wemmelund H; Høgh A; Hundborg HH; Johnsen SP; Lindholt JS
Pharmacoepidemiol Drug Saf; 2016 Feb; 25(2):141-50. PubMed ID: 26817783
[TBL] [Abstract][Full Text] [Related]
47. Incidence, predictors and clinical characteristics of orolingual angio-oedema complicating thrombolysis with tissue plasminogen activator for ischaemic stroke.
Hurford R; Rezvani S; Kreimei M; Herbert A; Vail A; Parry-Jones AR; Douglass C; Molloy J; Alachkar H; Tyrrell PJ; Smith CJ
J Neurol Neurosurg Psychiatry; 2015 May; 86(5):520-3. PubMed ID: 25016564
[TBL] [Abstract][Full Text] [Related]
48. To RAS or not to RAS? The evidence for and cautions with renin-angiotensin system inhibition in patients with diabetic kidney disease.
St Peter WL; Odum LE; Whaley-Connell AT
Pharmacotherapy; 2013 May; 33(5):496-514. PubMed ID: 23576066
[TBL] [Abstract][Full Text] [Related]
49. Angiotensin II receptor blockers in patients with ACE inhibitor-induced angioedema.
Warner KK; Visconti JA; Tschampel MM
Ann Pharmacother; 2000 Apr; 34(4):526-8. PubMed ID: 10772441
[TBL] [Abstract][Full Text] [Related]
50. Brief review: angiotensin converting enzyme inhibitors and angioedema: anesthetic implications.
Sarkar P; Nicholson G; Hall G
Can J Anaesth; 2006 Oct; 53(10):994-1003. PubMed ID: 16987854
[TBL] [Abstract][Full Text] [Related]
51. Potential genetic risk factors in angiotensin-converting enzyme-inhibitor-induced angio-oedema.
Bas M; Hoffmann TK; Tiemann B; Dao VT; Bantis C; Balz V; Schultz-Coulon HJ; Stark T; Schuler P; Greve J; Ivens K; Bier H; Kojda G
Br J Clin Pharmacol; 2010 Feb; 69(2):179-86. PubMed ID: 20233181
[TBL] [Abstract][Full Text] [Related]
52. [Iatrogenic angioedema due to estrogen, angiotensin conversion enzyme inhibitors, angiotensin receptor antagonists and dialysis membranes].
Drouet C; Ponard D; Bouillet L
Rev Med Interne; 2006 Jun; 27 Suppl 2():S76-9. PubMed ID: 16697083
[No Abstract] [Full Text] [Related]
53. Angio-oedema and ACE inhibitors.
Black PN; Simpson IJ
Aust N Z J Med; 1995 Dec; 25(6):746; author reply 747. PubMed ID: 8770348
[No Abstract] [Full Text] [Related]
54. ACE inhibitor- versus angiotensin II blocker-induced cough and angioedema.
Pylypchuk GB
Ann Pharmacother; 1998 Oct; 32(10):1060-6. PubMed ID: 9793599
[TBL] [Abstract][Full Text] [Related]
55. Angio-oedema and ACE inhibitors.
Boyd IW
Aust N Z J Med; 1995 Dec; 25(6):746-7. PubMed ID: 8770349
[No Abstract] [Full Text] [Related]
56. Failure to recognise the association of life-threatening angio-oedema and angiotensin-converting enzyme inhibitor therapy.
Weiner JM
Aust N Z J Med; 1995 Jun; 25(3):241-2. PubMed ID: 7487694
[No Abstract] [Full Text] [Related]
57. Is there benefit in dual renin-angiotensin-aldosterone system blockade? No, yes and maybe: a guide for the perplexed.
Wong J
Diab Vasc Dis Res; 2013 May; 10(3):193-201. PubMed ID: 23349369
[TBL] [Abstract][Full Text] [Related]
58. Renin-Angiotensin System Blockage and Avoiding High Doses of Calcineurin Inhibitors Prevent Interstitial Fibrosis and Tubular Atrophy in Kidney Transplant Recipients.
Sayin B; Canver B; Gurlek Demirci B; Colak T; Ozdemir BH; Haberal M
Exp Clin Transplant; 2017 Feb; 15(Suppl 1):32-36. PubMed ID: 28260428
[TBL] [Abstract][Full Text] [Related]
59. Late angio-oedema in patients taking angiotensin-converting-enzyme inhibitors.
Pavletic AJ
Lancet; 2002 Aug; 360(9331):493-4. PubMed ID: 12241757
[No Abstract] [Full Text] [Related]
60. Is there an embryopathy associated with first-trimester exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists? A critical review of the evidence.
Polifka JE
Birth Defects Res A Clin Mol Teratol; 2012 Aug; 94(8):576-98. PubMed ID: 22807387
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
